NEW YORK, March 16 (GenomeWeb News) -Oxford Genome Sciences will use its proteomics platform and its Oxford Genome Anatomy Project to evaluate biomarkers linked to breast cancer for Bayer HealthCare's diagnostics division, the companies said today.
Though financial terms of the agreement were not disclosed, Bayer said it "has committed program funding" to
Bayer HealthCare hopes this research will help it discover and develop therapeutic and diagnostic products for breast cancer.
According to